GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Concept Inc (NAS:VERO) » Definitions » EPS (Diluted)

Venus Concept (Venus Concept) EPS (Diluted) : $-6.68 (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Venus Concept EPS (Diluted)?

Venus Concept's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.68. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.68.

Venus Concept's EPS (Basic) for the three months ended in Mar. 2024 was $-1.68. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.68.

Venus Concept's EPS without NRI for the three months ended in Mar. 2024 was $-1.71. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.32.

During the past 3 years, the average EPS without NRIGrowth Rate was 36.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 50.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Venus Concept's highest 3-Year average EPS without NRI Growth Rate was 68.20% per year. The lowest was 4.80% per year. And the median was 42.90% per year.


Venus Concept EPS (Diluted) Historical Data

The historical data trend for Venus Concept's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Concept EPS (Diluted) Chart

Venus Concept Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -71.55 -34.95 -6.30 -9.94 -6.84

Venus Concept Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -1.35 -1.64 -2.01 -1.68

Competitive Comparison of Venus Concept's EPS (Diluted)

For the Medical Devices subindustry, Venus Concept's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Concept's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Concept's PE Ratio distribution charts can be found below:

* The bar in red indicates where Venus Concept's PE Ratio falls into.



Venus Concept EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Venus Concept's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-37.25-0)/5.442
=-6.84

Venus Concept's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.794-0)/5.829
=-1.68

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Concept  (NAS:VERO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Venus Concept EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Venus Concept's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Concept (Venus Concept) Business Description

Traded in Other Exchanges
N/A
Address
235 Yorkland Boulevard, Suite 900, Toronto, ON, CAN, M2J 4Y8
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Heal, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
Executives
Anthony Natale director 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Ross Portaro officer: President Global Sales 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Michael Willingham Masters 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Silva Rajiv De director, officer: Chief Executive Officer 1400 ATWATER DRIVE, MALVERN PA 19355
Stanley Tyler Hollmig director 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Hemanth Jacob Varghese officer: President/Chief Bus. Officer 330 JOICEY BOULEVARD, TORONTO A6 M5M2W1
Marlin Fund, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Capital Management Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund Iii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Master Fund Offshore Ii, Lp 10 percent owner WAYSTONE CORP SV (CAYMAN) LTD, STE 5B201, FL 2, 1 NEXUS WAY, CAMANA BAY, BOX 1344, GRAND CAYMAN E9 KY1-1108
Mss Vc Spv Lp 10 percent owner C/O MASTERS SPECIAL SITUATIONS, LLC, 3060 PEACHTREE ROAD, NW, STE.1425, ATLANTA GA 30305
Marlin Fund Ii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Special Situations, Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Penna Domenic Della officer: Chief Financial Officer 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Anna Georgiadis officer: VP, Global HR 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8

Venus Concept (Venus Concept) Headlines

From GuruFocus

Venus Concept Announces 1-for-15 Reverse Stock Split

By sperokesalga sperokesalga 05-11-2023